Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

  • STATUS
    Recruiting
  • days left to enroll
    15
  • participants needed
    6
  • sponsor
    Istari Oncology, Inc.
Updated on 13 February 2022
estrogen
progesterone
residual tumor
epidermal growth factor receptor
progesterone receptor
triple-negative breast cancer
mammogram

Summary

This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.

Description

The study drug PVSRIPO is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). The purpose of this pilot study is to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer. The hypothesis is that administration of PVSRIPO in the tumor causes inflammation, which stimulates innate and adaptive immune activation in invasive breast cancer. Enrollment target will include six women with invasive breast cancer. Women with stage II-IV invasive breast cancer with at least 1 cm of residual tumor after chemotherapy and scheduled for standard of care surgery will be eligible.

The objective of the study is to investigate PVSRIPO-mediated inflammation and immunity in women invasive breast cancer. The primary exploratory objective is to describe the change in the amount of tumor infiltrating immune cells in tumor tissue pre- and post-injection of PVSRIPO by H&E (Haemotoxylin and Eosin).

Other exploratory objectives are: 1.) to examine tumor tissue pre- and post-injection of PVSRIPO for inflammatory and immune signature using arrays, CD155 expression by immunohistochemistry (IHC), immune cell infiltrate by IHC and tumor infiltrating immune cells using flow cytometry (post-injection only); and 2) To examine blood for inflammatory and immune signature using arrays, immune cell composition (antigen presenting cells, B cells and T cells), T cell activation by flow cytometry and B cell activation by ELISA and peptide arrays. Blood will be collected on day -7 (before polio vaccine booster), day 0 (before PVSRIPO injection), day 2 (after PVSRIPO), day 14 (after PVSRIPO before surgery), and in follow-up at months 1 and 6 post-PVSRIPO.

Details
Condition Invasive Breast Cancer
Treatment PVSRIPO
Clinical Study IdentifierNCT03564782
SponsorIstari Oncology, Inc.
Last Modified on13 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years
Confirmation of invasive breast cancer including any of the following
Triple-negative breast cancer defined as receptor status being estrogen receptor expression 10%, progesterone receptor expression 10%, and HER2/Neu expression by IHC 0 or 1+, or 2+ with fluorescence in situ hybridization confirming no amplification of HER2 on a pretreatment tumor sample
Hormone positive breast cancer defined as receptor status being estrogen receptor expression > 10%, progesterone receptor expression > 10% prior to initiation of chemotherapy
HER2+ breast cancer defined as HER2/Neu expression by IHC 3+ or fluorescence in situ hybridization confirming amplification of HER2 on a pretreatment tumor sample prior to initiation of chemotherapy. HER2+ and hormone positive (ie triple positive) breast cancers are included in this study
Stage II-III invasive breast cancer with 1 cm of residual tumor based on MRI, mammogram, ultrasound, or breast clinical exam as SOC after completion of neoadjuvant chemotherapy, OR Stage IV BC with 1 cm locally recurrent disease (i.e. chest wall recurrence only)
ECOG 1
Hemoglobin 9.0 g/dl, ANC 1,500 cells/l, platelets 100,000 cells/l
Women must have had last dose of chemotherapy at least 3 weeks prior to treatment with PVSRIPO
Women must have at least 2 weeks minimum (ideal 3-4 weeks) of a wash-out period after any steroid administration (IV, PO, or intraocular)
Serum creatinine 1.5 mg/dl, serum SGOT and bilirubin 1.5 times ULN (upper limit of normal)
Women must provide written informed consent prior to enrollment on study, prior to conduct of screening procedures and enrollment on study
Women of childbearing potential will have a negative serum pregnancy test at screening
Women of childbearing potential must be willing to avoid pregnancy for the course of the study through 120 days after PVSRIPO injection
Surgical resection of the tumor is planned and patient is willing to undergo surgical resection of the cancer

Exclusion Criteria

T1 N0 invasive breast cancer
Breast cancer with skin necrosis
Concurrent immune therapy, chemotherapy, or steroid therapy
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to polio vaccine booster
Has a known diagnosis of immunodeficiency
Has a known additional malignancy that is progressing or requires active treatment
Has known active central nervous system metastases and/or carcinomatous meningitis
Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease or a syndrome that requires systemic steroids or immunosuppressive agents
Has an active infection requiring systemic therapy
Has known psychiatric or substance abuse disorders that would interfere with the requirements of the trial
Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 120 days after trial treatment
Has received prior therapy with an anti-PD-1, anti-PDL-1, anti-PDL-2, anti-CD137, or anti-CTLA-4 (or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways)
Has a known history of Human Immunodeficiency Virus (HIV)
Has known active Hepatitis B or Hepatitis C
Active liver disease with elevated transaminases > 2x ULN
Has received a live vaccine within 30 days prior to PVSRIPO treatment
Inactivated vaccines are acceptable and are not an exclusion criterion
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note